Quantitative studies of the kinetics of 5-aminolaevulinic acid-induced fluorescence in bladder transitional cell carcinoma.
Photodynamic therapy is a potential treatment for superficial bladder cancer that utilizes photosensitizer drugs, which are activated by light to cause tissue destruction. However, first-generation photosensitizers cause prolonged phototoxicity, have poor tumour specificity and can accumulate within detrusor muscle, resulting in permanent loss of bladder capacity following treatment. A newer drug, called 5-aminolaevulinic acid (ALA), generates a sensitizer called protoporphyrin IX (PpIX) in situ and has been shown, qualitatively, to be more tumour specific. The fluorescence kinetics of ALA-induced PpIX was investigated in patient biopsies of bladder tumour, normal urothelium and detrusor muscle, both in vitro after incubation of specimens in ALA-rich culture medium for various times and in vivo after instillation of intravesical ALA before endoscopic resection. The fluorescence in tumour tissue was twice that of normal urothelium in vitro and up to tenfold in vivo. There was little ALA-induced fluorescence in detrusor muscle, both in vitro and in vivo. Most importantly, no patients experienced phototoxicity or other adverse events following intravesical instillation of ALA.
Datta
S N
SN
Department of Urology, University Hospital of Wales, Cardiff, UK.
Loh
C S
CS
MacRobert
A J
AJ
Whatley
S D
SD
Matthews
P N
PN
D000283:Administration, Intravesical; D000368:Aged; D000622:Aminolevulinic Acid / Q000008:administration & dosage / Q000378:metabolism*; D001706:Biopsy; D002295:Carcinoma, Transitional Cell / Q000378:metabolism*; D046508:Culture Techniques; D005453:Fluorescence; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D017319:Photosensitizing Agents / Q000378:metabolism*; D011166:Porphyrins / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000378:metabolism*
D017319:Photosensitizing Agents; D011166:Porphyrins; D000622:Aminolevulinic Acid